Recently published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), VHIO investigators have established…
Results of a study led by María Abad, Principal Investigator of VHIO’s Cellular Plasticity and Cancer Group, identify a new…
Published today, Clarivate has revealed its annual #HighlyCited2022 researchers list. Featuring among the world’s elite scientists at academic research institutes and…
Co-authored by Ana Vivancos, Principal Investigator of VHIO’s Cancer Genomics Group, and VHIO’s Director Josep Tabernero, a News & Views…
The oncology channel ecancer recently launched a new series of videos focused on Genomics in Oncology. Leading experts are invited…
Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few…
This is shown in the results of the CheckMate 915 study, in which Dr. Eva Muñoz-Couselo, investigator in the Breast…
Now published in ESMO Perspectives digital magazine, the latest edition of On Target – Artificial Intelligence: a ‘smart’ arrow in our quiver against cancer –…
Published in Nature Medicine, a VHIO-led study has unveiled a new predictive biomarker of response to anti-BRAF/EGFR combinatory therapy in…
The Coordination and Support Action “4.UNCAN.eu” had its official kick-off on September 8-9 2022 with a public event hosted by…
Results of the DUTHY exploratory phase II study evaluating dual immune checkpoint blockade with durvalumab and tremelimumab show promising activity…
Presented at the 2022 annual Congress of the European Society for Medical Oncology (ESMO), results from three studies co-authored by…
